US 12,227,506 B2
Crystalline polymorphs of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
Thirumalai Rajan Srinivasan, Hyderabad (IN); Eswaraiah Sajja, Hyderabad (IN); Vijayavitthal T Mathad, Hyderabad (IN); Rajeshwar Reddy Sagyam, Hyderabad (IN); Srinivasulu Rangineni, Hyderabad (IN); and Venkata Narasayya Saladi, Hyderabad (IN)
Assigned to MSN LABORATORIES PRIVATE LIMITED, R&D CENTER, Telangana (IN)
Appl. No. 17/432,938
Filed by MSN LABORATORIES PRIVATE LIMITED, R&D CENTER, Telangana (IN)
PCT Filed Feb. 19, 2020, PCT No. PCT/IN2020/050154
§ 371(c)(1), (2) Date Aug. 23, 2021,
PCT Pub. No. WO2020/170270, PCT Pub. Date Aug. 27, 2020.
Prior Publication US 2024/0199615 A1, Jun. 20, 2024
Int. Cl. C07D 487/04 (2006.01); A61K 31/519 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1

OG Complex Work Unit Chemistry
characterized by its PXRD pattern peaks at about 6.3, 10.0, 12.8, 13.7, 17.2, 18.1, 19.4, 20.2, 20.9, 21.6, 23.1, 23.7, 24.6, 26.2 and 27.7±0.2° of 2θ.